卡培他滨联合奥沙利铂治疗晚期结直肠癌的疗效及对生活质量的影响

目的:探讨卡培他滨联合奥沙利铂治疗晚期结直肠癌患者的临床疗效及对患者生活质量的影响。方法:选取我院2013年3月-2015年12月收治的40例晚期结直肠癌患者,按乱数表法分为观察组和对照组各20例。对照组给予卡培他滨治疗,观察组给予卡培他滨联合奥沙利铂治疗,两组均治疗3周期。对比两组患者治疗后4周的客观缓解率和临床受益率,对比两组患者治疗前、治疗后4周的功能状态评分(KPS)和体力状况评分(ZPS),对比两组患者6个月、1年生存率以及并发症发生率。结果:治疗后4周观察组临床受益率和客观缓解率显著高于对照组,差异有统计学意义(P0.05);与治疗前相比,治疗后4周两组KPS评分显著升高,ZPS评分显著降低,差异均有统计学意义(P0.05);与对照组相比,治疗后4周观察组KPS评分显著升高,ZPS评分显著降低,差异均有统计学意义(P0.05);两组患者在治疗过程中恶心呕吐、口腔黏膜炎、贫血、血小板减少、白细胞减少、腹泻等并发症发生率比较差异均无统计学意义(P0.05);观察组1年生存率显著高于对照组,差异有统计学意义(P0.05)。结论:卡培他滨联合奥沙利铂治疗晚期结直肠癌患者疗效较好,能提高患者的客观缓解率、临床受益率、生活质量和1年生存率,较单用卡培他滨治疗优势明显,值得临床推广。

Curative Effect of Capecitabine Combined with Oxaliplatin in the Treatment of Advanced Colorectal Cancer and Its Impact on Quality of Life

ABSTRACT Objective: To explore the curative effect of capecitabine combined with oxaliplatin in the treatment of advanced colorectal cancer and its impact on quality of life. Methods: 40 patients with advanced colorectal cancer who were treated in our hospital from March 2013 to December 2015 were selected as research object, they were divided into observation group and control group as each group 20 cases by random number table method. The control group was treated with capecitabine, the observation group was treated with capecitabine combined with oxaliplatin, two groups were treated for 9 weeks. The objective response rate and clinical benefit rate of the two groups were compared after treatment for 4 weeks, the functional status score (KPS) and physical status score (ZPS) of the two groups were compared at before treatment and 4 weeks after treatment, the 6 month, the 1 year survival rate and the complication rate of the patients in the two groups were compared. Results: The objective response rate and clinical benefit rate in the observation group were significantly higher than those in the control group at 4 weeks after treatment, the differences were statistically significant (P<0.05);Compared with before treatment, the KPS scores of the two groups were significantly increased, and the ZPS score was significantly lower, the differences were statistically significant (P<0.05); Compared with the control group, the KPS score of observation group was significantly increased at 4 weeks after treatment, and the ZPS score was significantly lower, the differences were statistically significant (P<0.05); The incidence of nausea and vomiting, oral mucosal inflammation, anemia, thrombocytopenia, white blood cell reduction,diarrhea of the two groups were no significant differences (P>0.05); The 1 year survival rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (P<0.05). Conclusion: Capecitabine with oxaliplatin has a remarkable clinical curative effect treatment of advanced colorectal cancer, can improve the patient''s the objective response rate, clinical benefit rate, quality of life and 1 year survival rate, compare with capecitabine alone is obvious advantages, worthy of clinical promotion.